Rabies virus glycoprotein and immune response pattern using recombinant protein or recombinant RNA viral vectors

Autor(es)

Astray, Renato M. ; Ventini, Daniella C. ; Boldorini, Vera L. L. ; Silva, Fernanda G. ; Rocca, Mayra P. ; Pereira, Carlos A.

• Tipo de documento: Artigo Científico
• Fonte: Vaccine; v. 32, n. 24, p. 4-pg., 2014-05-19.

Resumo

The present study shows the humoral and cellular aspects of immune response generated by a recombinant rabies virus glycoprotein (rRVGP) as compared to those generated by viral vector carrying the RNA coding for this protein (RVGP-RNA). The rRVGP was synthesized by stably transfected Drosophila melanogaster Schneider 2 (S2) cells and the RVGP-RNA was carried by a recombinant Semiliki Forest Virus (SFV-RVGP). The data show that protein as well as the RNA vaccine was capable of inducing reasonably acceptable levels of antibodies as compared to the optimized commercial whole virus vaccine. As expected, the RNA vaccine was clearly more effective than the protein vaccines in inducing a cellular immune response, as evaluated by the IgG2a/IgG1 ratio and synthesis of interferon gamma (IFN gamma) and interleukin 2 (IL2). Our study supports the importance of vaccine designing taking into consideration the concept of DNA/RNA ability to induce an effective cell immune response. (C) 2014 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 09/09327-7 - Desenvolvimento de bioprocesso com células S2 para produção e purificação da glicoproteina recombinante do vírus da raiva (GPV) e estudo de sua antigenicidade
• Beneficiário: Carlos Augusto Pereira
• Modalidade de apoio: Auxílio à Pesquisa - Regular